Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM 124-E in NASH
NCT01466894Phase 2Withdrawn
- Sponsor
- Immuron Limited
- Start
- Dec 2012
- Primary completion
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
A Phase 2 trial of IMM-124E in Nonalcoholic steatohepatitis (NASH), sponsored by Immuron Limited. Planned start Dec 2012; status: withdrawn.
02
Drugs
IMM-124E
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01466894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466894.